共 50 条
The past, present and future of anticholinergic drugs
被引:2
|作者:
Healy, David
[1
]
机构:
[1] Data Based Med Amer Ltd, 95 Sandringham Dr, Toronto, ON M3H 1E1, Canada
关键词:
anticholinergic drugs;
cognitive burden;
confusion;
deliriants;
deprescribing;
peripheral neuropathy;
TRIALS COMPARING ANTIDEPRESSANTS;
BURDEN INDEX;
METAANALYSIS;
SYMPTOMS;
CLOMIPRAMINE;
MEDICATIONS;
CITALOPRAM;
DISEASE;
SYSTEM;
D O I:
10.1177/20451253231176375
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
In current medical practice, it is difficult to find any reports claiming that drugs that are primarily anticholinergic or those that have significant anticholinergic effects have any therapeutic benefits. These drugs fell into disrepute within the mental health field from the mid-1960s onwards, and their supposed problems extended to elsewhere in medicine after that. There is considerable evidence that this disrepute stemmed more from marketing copy rather than from hard clinical trial data. Many apparent reviews appear to repeat prior claims rather than present substantial or new evidence. This article offers a perspective rather than a systematic review as there is little evidence other than claims to review. The aim is to challenge the conventional narrative that anticholinergic effects are uniquely hazardous by pointing to the uncertain basis for claims about the harms of anticholinergic drugs, antimuscarinic drugs in particular, ending with pointers to recent research that, if realized, might underpin important possible future benefits.
引用
收藏
页数:9
相关论文